Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | NAMPT | P43490 | 7/20 | 0.71 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.71 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31610757 | 1.00 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53NAMPT | |
| SCHEMBL12079361 | 0.89 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2NAMPTCYP11B1 | |
| SCHEMBL21561728 | 0.85 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53LMNA | |
| SCHEMBL14082561 | 0.85 | NPC1 (0.74) | RAB9ANPC1SMN1; SMN2TP53NAMPT | |
| SCHEMBL12017790 | 0.85 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2TP53NAMPT | |
| SCHEMBL12017613 | 0.85 | BRAF (0.79) | RAB9ANPC1SMN1; SMN2TP53NAMPT | |
| SCHEMBL23987239 | 0.84 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2TP53NAMPT | |
| SCHEMBL10978857 | 0.83 | CYP11B1 (1.00) | RAB9ANPC1SMN1; SMN2NAMPTCYP11B1 | |
| SCHEMBL12078341 | 0.83 | NAMPT (0.77) | RAB9ANPC1SMN1; SMN2NAMPTCYP11B1 | |
| SCHEMBL3403542 | 0.83 | NAMPT (0.73) | RAB9ANPC1SMN1; SMN2TP53NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | RAB9A 2995/4885NPC1 35/4885SMN1; SMN2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.